Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01087125 · ClinicalTrials.gov registry record
Abatacept Pregnancy Exposure Registry
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 42
- Enrollment target
NCT01087125: Completed study, sponsored by Bristol-Myers Squibb.
NCT01087125 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01087125 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The purpose of the abatacept pregnancy registry is to monitor planned and unplanned pregnancies exposed to abatacept, to evaluate the possible teratogenic effects (that is, any abnormal development) of this medication in the pregnancy outcome and to follow live born infants for one year after birth.
Interventions
- DRUG No Interventions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2006-09-01 |
| Est. Completion | 2019-12-31 |
What the finished NCT01087125 record still lists
NCT01087125 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Interventions is the first listed.
NCT01087125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01087125 about?
NCT01087125 is a clinical study titled "Abatacept Pregnancy Exposure Registry". The purpose of the abatacept pregnancy registry is to monitor planned and unplanned pregnancies exposed to abatacept, to evaluate the possible teratogenic effects (that is, any abnormal development) of this medication in the pregnancy outcome and to follow live born infants for one year after birth.
What is the current status of trial NCT01087125?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2006-09-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT01087125?
The interventions under investigation include: No Interventions (DRUG).
Who is sponsoring clinical trial NCT01087125?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI